Pharmaceuticals Stocks

McKesson Corp (MCK) Annual Valuation – 2014

McKesson Corp is not suitable for either the Defensive Investor or the Enterprising Investor. The Defensive Investor has concerns with the low current ratio, lack of earnings stability over the last ten years, and the high PEmg and PB ratios, while the Enterprising Investor is concerned with the high level of debt relative to the current assets.

Read More
Pharmaceuticals Stocks

Regeneron Pharmaceuticals Inc. (REGN) Annual Valuation – 2014

Regeneron Pharmaceuticals is not suitable for either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company has shown insufficient earnings stability or growth over the ten year historical period, does not pay dividends, and is trading at a high PEmg ratio.

Read More
Back To Top